Natural Product (NP) Details
| General Information of the NP (ID: NP4621) | |||||
|---|---|---|---|---|---|
| Name |
Triptolide
|
||||
| Synonyms |
Triptolid; PG490; UNII-19ALD1S53J; NSC 163062; CHEMBL463763; CHEBI:9747; 19ALD1S53J; C20H24O6; PG-490; CPD000466307; Triptolide, Tripterygium wilfordii; (-)-Triptolide; PG 490; Trisoxireno(4b,5:6,7:8a,9)phenanthro(1,2-c)furan-1(3H)-one, 3b,4,4a,6,6a,7a,7b,8b,9,10-decahydro-6-hydroxy-8b-methyl-6a-(1-methylethyl)-, (3bS,4aS,5aS,6R,6aR,7aS,7bS,8aS,8bS)-; SMR000466307; NSC163062; Triptolide, 1; Triptolide(PG490)/; AC1Q6AXN; BSPBio_001595; KBioGR_000315; KBioSS_000315
Click to Show/Hide
|
||||
| Species Origin | Tripterygium hypoglaucum ... | Click to Show/Hide | |||
| Tripterygium hypoglaucum | |||||
| Disease | Diabetes mellitus [ICD-11: 5A10] | Phase 3 | [1] | ||
| Structure |
|
Click to Download Mol2D MOL |
|||
| ADMET Property |
Absporption
Caco-2 Permeability
-5.121
MDCK Permeability
-4.768
PAMPA
- -
HIA
- - -
Distribution
VDss
0.134
PPB
79.9%
BBB
- -
Metabolism
CYP1A2 inhibitor
- - -
CYP1A2 substrate
- -
CYP2C19 inhibitor
- - -
CYP2C19 substrate
- -
CYP2C9 inhibitor
- - -
CYP2C9 substrate
- - -
CYP2D6 inhibitor
- - -
CYP2D6 substrate
- - -
CYP3A4 inhibitor
- - -
CYP3A4 substrate
-
CYP2B6 inhibitor
- -
CYP2B6 substrate
- - -
CYP2C8 inhibitor
+
HLM Stability
++
Excretion
CLplasma
8.189
T1/2
1.817
Toxicity
DILI
+
Rat Oral Acute Toxicity
++
FDAMDD
++
Respiratory
-
Human Hepatotoxicity
-
Ototoxicity
+
Drug-induced Nephrotoxicity
++
Drug-induced Neurotoxicity
++
Hematotoxicity
+
Genotoxicity
++
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++).
2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
Click to Show/Hide
|
||||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
| Formula |
C20H24O6
|
||||
| PubChem CID | |||||
| Canonical SMILES |
CC(C)C12C(O1)C3C4(O3)C5(CCC6=C(C5CC7C4(C2O)O7)COC6=O)C
|
||||
| InChI |
1S/C20H24O6/c1-8(2)18-13(25-18)14-20(26-14)17(3)5-4-9-10(7-23-15(9)21)11(17)6-12-19(20,24-12)16(18)22/h8,11-14,16,22H,4-7H2,1-3H3/t11-,12-,13-,14-,16+,17-,18-,19+,20+/m0/s1
|
||||
| InChIKey |
DFBIRQPKNDILPW-CIVMWXNOSA-N
|
||||
| CAS Number |
CAS 38748-32-2
|
||||
| Herb ID | |||||
| ETMC ID | |||||
| SymMap ID | |||||
| TCMSP ID | |||||
| TTD Drug ID | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
| Temozolomide | Brain cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CCND1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | PARP1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | RELA | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | XIAP | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | GIC-1 | Glioblastoma multiforme | Homo sapiens | |||
| Experimental
Result(s) |
TPL sensitizes GICs to TMZ by synergistically enhancing apoptosis, which is likely resulting from the augmented repression of NF-KappaB signaling. | |||||
| BIIB021 | Breast cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [3] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BIRC5 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | EIF4EBP1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | mTOR | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | p105 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | S6K1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | TP53 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | XIAP | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | 8505C | CVCL_1054 | Thyroid gland anaplastic carcinoma | Homo sapiens | ||
| TPC-1 | CVCL_6298 | Thyroid gland papillary carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
The synergism between BIIB021 and triptolide in induction of cytotoxicity is associated with the inhibition of PI3K/Akt/mTOR and NF-KappaB signal pathways, the underexpression of survivin and the activation of DNA damage response in thyroid carcinoma cells. | |||||
| Venetoclax | Chronic lymphocytic leukaemia | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [4] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BBC3 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | BCL2L11 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | BID | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP9 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MCL1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | PARP1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | PMAIP1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | MV4-11 | CVCL_0064 | Childhood acute monocytic leukemia | Homo sapiens | ||
| MOLM-13 | CVCL_2119 | Adult acute myeloid leukemia | Homo sapiens | |||
| U-937 | CVCL_0007 | Adult acute monocytic leukemia | Homo sapiens | |||
| THP-1 | CVCL_0006 | Childhood acute monocytic leukemia | Homo sapiens | |||
| KG-1a | CVCL_1824 | Adult acute myeloid leukemia | Homo sapiens | |||
| Experimental
Result(s) |
Combining triptolide with ABT-199 is effective against acute myeloid leukemia through reciprocal regulation of Bcl-2 family proteins and activation of the intrinsic apoptotic pathway. | |||||
| Cetuximab | Colorectal cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [5] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | POLR2A | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
| NCI-H1299 | CVCL_0060 | Lung large cell carcinoma | Homo sapiens | |||
| UM-SCC-6 | CVCL_7773 | Tongue squamous cell carcinoma | Homo sapiens | |||
| NCI-H520 | CVCL_1566 | Lung squamous cell carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Cetuximab-Triptolide conjugate suppresses the growth of EGFR-overexpressing lung cancers through targeting RNA polymerase II. | |||||
| Oxaliplatin | Colorectal cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [6] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | LEF1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | TCF7 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | SW480 | CVCL_0546 | Colon adenocarcinoma | Homo sapiens | ||
| In-vivo Model | SW480 cells were subcutaneously injected into the back of the mice (2*106 cells in 200 mL of medium). | |||||
| Experimental
Result(s) |
Triptolide synergistically enhances antitumor activity of oxaliplatin in colon carcinoma in vitro and in vivo. | |||||
| Tumor necrosis factor alpha | Colorectal cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [7] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Cleavage | COL11A2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | MDA-MB-231 | CVCL_0062 | Breast adenocarcinoma | Homo sapiens | ||
| MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Triptolide sensitized human breast cancer cells to TNF Alpha induced apoptosis. | |||||
| Erlotinib | Lung cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [8] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | EGFR | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | NCI-H1975 | CVCL_1511 | Lung adenocarcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Combined treatment with triptolide and tyrosine kinase inhibitors synergistically enhances apoptosis in non-small cell lung cancer H1975 cells but not H1299 cells through EGFR/Akt pathway. | |||||
| TNF-related apoptosis inducing ligand | Lung cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [9] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | HSPA4 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | ACHN | CVCL_1067 | Papillary renal cell carcinoma | Homo sapiens | ||
| A-498 | CVCL_1056 | Renal cell carcinoma | Homo sapiens | |||
| Caki-1 | CVCL_0234 | Clear cell renal cell carcinoma | Homo sapiens | |||
| 769-P | CVCL_1050 | Renal cell carcinoma | Homo sapiens | |||
| 786-O | CVCL_1051 | Renal cell carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Triptolide sensitizes RCC cells to TRAIL-induced apoptosis through altered TRAIL death receptor and heat shock protein expression. | |||||
| AMD3100 | Malignant haematopoietic neoplasm | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [10] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BIRC5 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CBY1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CCND1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | ERK1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | ERK2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MMP-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MMP-9 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MYC | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | PARP1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | STAT3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | VEGFA | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | MG-63 | CVCL_0426 | Osteosarcoma | Homo sapiens | ||
| U2OS | CVCL_0042 | Osteosarcoma | Homo sapiens | |||
| SaOS-2 | CVCL_0548 | Osteosarcoma | Homo sapiens | |||
| 143B | CVCL_2270 | Osteosarcoma | Homo sapiens | |||
| HOS-8603 | Osteosarcoma | Homo sapiens | ||||
| Experimental
Result(s) |
AMD3100 combined with triptolide can reduce proliferation and metastasis, and induce apoptosis of U2OS cells, which may be related to the Erk1/2, Akt, STAT3 and NF-KappaB pathways. | |||||
| Aspirin | Pain | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [11] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CCNE1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CDKN1A | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | HeLa | CVCL_0030 | Endocervical adenocarcinoma | Homo sapiens | ||
| SiHa | CVCL_0032 | Cervical squamous cell carcinoma | Homo sapiens | |||
| Ca Ski | CVCL_1100 | Cervical squamous cell carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Aspirin and triptolide combination treatment has synergistic anti-tumor effects on cervical cancer cells. | |||||
| Vasostatin | Pancreatic endocrine tumor | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [12] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAD | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | BAK | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BCL-xL | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BIRC2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP8 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP9 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CFLAR | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MCL1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
| HCT 116 | CVCL_0291 | Colon carcinoma | Homo sapiens | |||
| HEK293 | CVCL_0045 | Healthy | Homo sapiens | |||
| QSG-7701 | CVCL_6944 | Human hepatocarcinoma | Homo sapiens | |||
| HUVEC | CVCL_2959 | Healthy | Homo sapiens | |||
| In-vivo Model | HCT116 cells in a solution containing 25 ml of culture medium and 25 ml of mouse sarcoma extracellular matrix (Matrigel) were injected subcutaneously into the dorsal flanks of mice. | |||||
| Experimental
Result(s) |
Herbal compound triptolide synergistically enhanced antitumor activity of vasostatin120-180. | |||||
| 5-LOX shRNA | Prostate cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [13] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | VEGFA | Molecule Info |
Pathway MAP
|
|
| In-vivo Model | 1*107 SW1990 cells in 100 uL phosphate-buffered saline (PBS) were injected into back of BALB/c nude mice. | |||||
| Experimental
Result(s) |
Triptolide augments the effects of 5-lipoxygenase RNA interference in suppressing pancreatic tumor growth in a xenograft mouse model. | |||||
| Lcotinib | Pulmonary hypertension | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [8] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | EGFR | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | NCI-H1975 | CVCL_1511 | Lung adenocarcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Combined treatment with triptolide and tyrosine kinase inhibitors synergistically enhances apoptosis in non-small cell lung cancer H1975 cells but not H1299 cells through EGFR/Akt pathway. | |||||
| Sorafenib | Renal cell carcinoma | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [14] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Activity | p105 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | Huh-7 | CVCL_0336 | Adult hepatocellular carcinoma | Homo sapiens | ||
| PLC/PRF/5 | CVCL_0485 | Adult hepatocellular carcinoma | Homo sapiens | |||
| In-vivo Model | Athymic nude mice were injected with 5*106 HuH-7 cells subcutaneously in the right flank in 100-mL aliquots mixed with Matrigel in 1:1 ratio. | |||||
| Experimental
Result(s) |
The combination of triptolide and sorafenib was superior to either drug alone in inducing apoptosis and decreasing viability, whereas triptolide alone was sufficient to decrease nuclear factor kappaB activity. | |||||
| 5-fluorouracil | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [15] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Up-regulation | ROS generation | ||||
| In-vitro Model | NCI-H630 | CVCL_1572 | Colorectal cancer | Homo sapiens | ||
| HCT 116 | CVCL_0291 | Colon carcinoma | Homo sapiens | |||
| RKO | CVCL_0504 | Colon carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
PG490 strongly enhanced the cytotoxicity of 5-FU. PG490 also simultaneously induced ROS and inhibited NF-KappaB activity and significantly enhanced the cytotoxic effect of 5-FU in three CRC cell lines in vitro. | |||||
| Gemcitabine | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [16] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CHK1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | H2AFX | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MCL1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | BxPC-3 | CVCL_0186 | Pancreatic ductal adenocarcinoma | Homo sapiens | ||
| PANC-1 | CVCL_0480 | Pancreatic ductal adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Triptolide synergistically increased gemcitabine-induced cell growth inhibition and apoptosis, in addition to the cooperative regulation of B-cell lymphoma 2 family proteins and loss of mitochondrial membrane potential. | |||||
| β. A List of Drug(s) Whose Resistance can be Reversed by This NP | ||||||
| Cisplatin | Bladder cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [17] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP9 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CDKN1A | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | GSK-3B | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | JNK1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | JUN | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | TP53 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | RT-112 | CVCL_1670 | Bladder carcinoma | Homo sapiens | ||
| RT-4 | CVCL_0036 | Bladder carcinoma | Homo sapiens | |||
| KK47 | CVCL_8253 | Bladder carcinoma | Homo sapiens | |||
| TCCSUP | CVCL_1738 | Bladder carcinoma | Homo sapiens | |||
| EJ | CVCL_ZC18 | B-cell lymphoma | Homo sapiens | |||
| J82 | CVCL_0359 | Bladder carcinoma | Homo sapiens | |||
| In-vivo Model | To produce a subcutaneous xenograft model, RT112 cells (5*106) were injected into the subcutaneous tissue of pathogen-free 6-week-old BALB/cAJcl-nu/nu mice. | |||||
| Experimental
Result(s) |
Cancer-specific enhancement of CDDP-induced cytotoxicity with triptolide effectively overcome the resistance to a CDDP-based conventional chemotherapy as a treatment for urothelial cancer through an interaction of inactivated glycogen synthase kinase-3beta with p53. | |||||
| Gefitinib | Lung cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [18] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | MMP-9 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | SNAI1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | VIM | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
| In-vivo Model | The A549/siE-cad cells (2*106) were injected subcutaneously into the underarms of the right forelimbs of 6-week-old BCLB/c mice. | |||||
| Experimental
Result(s) |
Triptolide inhibits epithelial mesenchymal transition and induces apoptosis in gefitinib resistant lung cancer cells. | |||||
| Cytarabine | Mantle cell lymphoma | Click to Show/Hide the Molecular Data of This Drug | ||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [19] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CASP9 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Phosphorylation | CHK1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | H2AFX | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | RAD53 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | NALM-6 | CVCL_0092 | Adult B acute lymphoblastic leukemia | Homo sapiens | ||
| In-vivo Model | To generate a mouse model of araC-resistant ALL, NALM-6/R cells (5 * 105) were subcutaneously injected into the angular veins of sublethally irradiated adult NSI (NOD/SCID IL2rg-/-) mice (20-30 g body weight, 2-3 months of age). | |||||
| Experimental
Result(s) |
Low dose triptolide reverses chemoresistance in adult acute lymphoblastic leukemia cells via reactive oxygen species generation and DNA damage response disruption. | |||||
| Doxorubicin | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [19] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CASP9 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Phosphorylation | CHK1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | H2AFX | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | RAD53 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | NALM-6 | CVCL_0092 | Adult B acute lymphoblastic leukemia | Homo sapiens | ||
| In-vivo Model | To generate a mouse model of araC-resistant ALL, NALM-6/R cells (5 * 105) were subcutaneously injected into the angular veins of sublethally irradiated adult NSI (NOD/SCID IL2rg-/-) mice (20-30 g body weight, 2-3 months of age). | |||||
| Experimental
Result(s) |
Low dose triptolide reverses chemoresistance in adult acute lymphoblastic leukemia cells via reactive oxygen species generation and DNA damage response disruption. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Nuclear factor NF-kappa-B (NFKB) | Molecule Info | [20] | |
| KEGG Pathway | MAPK signaling pathway | Click to Show/Hide | ||
| 2 | NF-kappa B signaling pathway | |||
| 3 | Osteoclast differentiation | |||
| 4 | Legionellosis | |||
| 5 | HTLV-I infection | |||
| 6 | Epstein-Barr virus infection | |||
| 7 | Pathways in cancer | |||
| 8 | Viral carcinogenesis | |||
| NetPath Pathway | IL5 Signaling Pathway | Click to Show/Hide | ||
| Panther Pathway | Apoptosis signaling pathway | Click to Show/Hide | ||
| 2 | B cell activation | |||
| 3 | Inflammation mediated by chemokine and cytokine signaling pathway | |||
| 4 | T cell activation | |||
| 5 | Toll receptor signaling pathway | |||
| Pathwhiz Pathway | Intracellular Signalling Through Adenosine Receptor A2a and Adenosine | Click to Show/Hide | ||
| 2 | Intracellular Signalling Through Adenosine Receptor A2b and Adenosine | |||
| Pathway Interaction Database | IL12-mediated signaling events | Click to Show/Hide | ||
| 2 | Alternative NF-kappaB pathway | |||
| Reactome | RIP-mediated NFkB activation via ZBP1 | Click to Show/Hide | ||
| 2 | DEx/H-box helicases activate type I IFN and inflammatory cytokines production | |||
| 3 | TAK1 activates NFkB by phosphorylation and activation of IKKs complex | |||
| 4 | Interleukin-1 processing | |||
| 5 | IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR) | |||
| 6 | IkBA variant leads to EDA-ID | |||
| 7 | Dectin-1 mediated noncanonical NF-kB signaling | |||
| 8 | NIK-->noncanonical NF-kB signaling | |||
| 9 | TRAF6 mediated NF-kB activation | |||
| WikiPathways | Toll-like receptor signaling pathway | Click to Show/Hide | ||
| 2 | DNA Damage Response (only ATM dependent) | |||
| 3 | SIDS Susceptibility Pathways | |||
| 4 | Nuclear Receptors Meta-Pathway | |||
| 5 | Cytosolic sensors of pathogen-associated DNA | |||
| 6 | TAK1 activates NFkB by phosphorylation and activation of IKKs complex | |||
| 7 | EBV LMP1 signaling | |||
| 8 | TNF alpha Signaling Pathway | |||
| 9 | TSLP Signaling Pathway | |||
| 10 | Neural Crest Differentiation | |||
| 11 | TWEAK Signaling Pathway | |||
| 12 | RANKL/RANK Signaling Pathway | |||
| 13 | RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways | |||
| 14 | Interleukin-1 processing | |||
| 15 | Folate Metabolism | |||
| 16 | Vitamin B12 Metabolism | |||
| 17 | Selenium Micronutrient Network | |||
| 18 | Regulation of toll-like receptor signaling pathway | |||